Recruiting APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST NCT06687070 Conditions Advanced Solid Tumor, Platinum-resistant Recurrent Ovarian Cancer Locations Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China View Trial Details
Recruiting A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. NCT06434610 Conditions Platinum-resistant Recurrent Ovarian Cancer Locations Beijing Cancer Hospital — Beijing, China The First Affiliated Hospital of Bengbu Medical University — Bengbu, China XiangYa Hospital CentralSouth University — Changsha, China Fujian Cancer Hospital — Fuzhou, China View all 17 locations View more locations Show fewer locations Loading locations... View Trial Details
Not Yet Recruiting Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer NCT07591831 Conditions Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more Locations Not specified View Trial Details
Not Yet Recruiting A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer NCT06509971 Conditions Platinum-resistant Recurrent Ovarian Cancer Locations Not specified View Trial Details
